2.04 USD
↘ 0.05 (2.39%)AT CLOSE (11:59 AM EDT)
Gain Therapeutics, Inc. Common Stock
GANXNASDAQ • USD
2.08
↗ 0.04 (1.96%)
POST MARKET (AS OF 06:33 PM EDT)
Post Market
AS OF 06:33 PM EDT
2.08
↗ 0.04 (1.96%)
Market: CLOSED
Open?$2.12
High?$2.14
Low?$2.02
Prev. Close?$2.09
Volume?337.9K
Avg. Volume?704.7K
VWAP?$2.08
Rel. Volume?0.48x
Bid / Ask
Bid?$2.01 × 300
Ask?$2.14 × 200
Spread?$0.13
Midpoint?$2.08
Valuation & Ratios
Market Cap?88.8M
Shares Out?42.2M
Float?35.6M
Float %?92.6%
P/E Ratio?N/A
P/B Ratio?4.78
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.63Strong
Quick Ratio?6.63Strong
Cash Ratio?6.22Strong
Debt/Equity?0.02Low
ValuationATTRACTIVELY VALUED
Score83/100
P/E?N/A▾
P/B?4.78FAIR▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.7CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-108.6%WEAK▾
ROA?-88.4%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$68.4M
News
Profile
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Employees
21
Market Cap
88.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-03-18
Address
4800 HAMPDEN LANE
BETHESDA, MD 20814
Phone: (301) 500-1556
BETHESDA, MD 20814
Phone: (301) 500-1556